NGF and osteosarcoma: When executed with these principles, testing of NGF/BDNF−directed agents alone and in combinations designed to normalize vascular and cytokine tone should determine whether neuromodulatory strategies can convert immunologically quiescent osteosarcoma into a treatment−responsive state.